LT3662910T - Trail geno indukcijai skirtas farmakoforas - Google Patents

Trail geno indukcijai skirtas farmakoforas

Info

Publication number
LT3662910T
LT3662910T LTEP19218049.5T LT19218049T LT3662910T LT 3662910 T LT3662910 T LT 3662910T LT 19218049 T LT19218049 T LT 19218049T LT 3662910 T LT3662910 T LT 3662910T
Authority
LT
Lithuania
Prior art keywords
pharmacophore
gene induction
trail gene
trail
induction
Prior art date
Application number
LTEP19218049.5T
Other languages
English (en)
Lithuanian (lt)
Inventor
Kim D Janda
Nicholas T. JACOB
Jonathan W. LOCKNER
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of LT3662910T publication Critical patent/LT3662910T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP19218049.5T 2014-03-31 2015-03-30 Trail geno indukcijai skirtas farmakoforas LT3662910T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461972689P 2014-03-31 2014-03-31

Publications (1)

Publication Number Publication Date
LT3662910T true LT3662910T (lt) 2024-12-27

Family

ID=54241169

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP19218049.5T LT3662910T (lt) 2014-03-31 2015-03-30 Trail geno indukcijai skirtas farmakoforas
LTEP15772254.7T LT3125898T (lt) 2014-03-31 2015-03-30 Farmakoforas, skirtas trail indukcijai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP15772254.7T LT3125898T (lt) 2014-03-31 2015-03-30 Farmakoforas, skirtas trail indukcijai

Country Status (20)

Country Link
US (5) US10239877B2 (cg-RX-API-DMAC7.html)
EP (3) EP3125898B1 (cg-RX-API-DMAC7.html)
JP (4) JP6756435B2 (cg-RX-API-DMAC7.html)
KR (2) KR102473930B1 (cg-RX-API-DMAC7.html)
CN (2) CN111499636B (cg-RX-API-DMAC7.html)
AU (4) AU2015241069B2 (cg-RX-API-DMAC7.html)
CA (2) CA2944452C (cg-RX-API-DMAC7.html)
CY (1) CY1123093T1 (cg-RX-API-DMAC7.html)
DK (2) DK3125898T3 (cg-RX-API-DMAC7.html)
ES (2) ES2779979T3 (cg-RX-API-DMAC7.html)
FI (1) FI3662910T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20241680T1 (cg-RX-API-DMAC7.html)
HU (2) HUE049013T2 (cg-RX-API-DMAC7.html)
LT (2) LT3662910T (cg-RX-API-DMAC7.html)
PL (2) PL3125898T3 (cg-RX-API-DMAC7.html)
PT (2) PT3662910T (cg-RX-API-DMAC7.html)
RS (2) RS60163B1 (cg-RX-API-DMAC7.html)
SI (2) SI3125898T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202000219T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015153468A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
AU2014244117B2 (en) 2013-03-13 2018-12-20 Oncoceutics, Inc. Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
KR102453679B1 (ko) * 2013-11-15 2022-10-11 온코슈틱스 인코포레이티드 7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조[1,2-a]피리도[3,4-e]피리미딘-5(1H)-온, 이의 염 및 이의 용도
RS60163B1 (sr) 2014-03-31 2020-05-29 Scripps Research Inst Farmakofor koji indukuje trail
CA3209515A1 (en) * 2015-01-30 2016-08-04 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs thereof, and salts thereof and methods for their use in therapy
CN104860948B (zh) * 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
KR102801670B1 (ko) * 2016-01-29 2025-04-25 온코슈틱스 인코포레이티드 이미프리돈에 의한 g 단백질-커플링된 수용체 (gpcr) 조절
AU2017310526B2 (en) 2016-08-12 2021-08-12 Edwin J. Iwanowicz Protein kinase regulators
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
GB2596010B (en) * 2019-02-11 2023-03-01 Madera Therapeutics Llc Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
EP3930714A4 (en) 2019-02-27 2022-10-26 Madera Therapeutics, LLC USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS
EP4192467A1 (en) 2020-08-06 2023-06-14 Eötvös Loránd Tudományegyetem Synthesis of novel imipridone derivatives and their evaluation for their anticancer activity
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN116751199B (zh) * 2023-06-02 2025-03-18 中国科学院基础医学与肿瘤研究所(筹) 一种线粒体蛋白酶靶向嵌合体、制备方法及用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE786028A (fr) * 1971-07-08 1973-01-08 Boehringer Sohn Ingelheim 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
JPS5374893A (en) 1976-12-15 1978-07-03 Fujitsu Ltd Driving method for semiconductor photosensitive device
JPS6132833U (ja) 1984-07-31 1986-02-27 日信工業株式会社 デイスクブレ−キ装置
US20050203110A1 (en) * 2002-05-23 2005-09-15 Coleman Paul J. Mitotic kinesin inhibitors
SI2303264T1 (en) 2008-06-09 2018-08-31 Allergan, Inc. Methods for treating alpha-adrenergic mediated states using imidazoline derivatives
CN102970868A (zh) * 2010-04-16 2013-03-13 柯瑞斯公司 具有k-ras突变的癌症的治疗
EP2648517B1 (en) * 2010-12-06 2015-08-05 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
EP2686332A2 (en) * 2011-03-15 2014-01-22 Chiesi Farmaceutici S.p.A. Isoxazolidine derivatives
US20140287931A1 (en) * 2011-04-04 2014-09-25 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
HUE068623T2 (hu) * 2011-04-29 2025-01-28 Penn State Res Found Normál és tumorsejtek kismolekulás TRAIL-génindukclója rákellenes terápiaként
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
AU2014244117B2 (en) * 2013-03-13 2018-12-20 Oncoceutics, Inc. Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9181237B2 (en) * 2013-10-04 2015-11-10 Mallinckrodt Llc Substituted berbines and their synthesis
RS60163B1 (sr) * 2014-03-31 2020-05-29 Scripps Research Inst Farmakofor koji indukuje trail

Also Published As

Publication number Publication date
JP2021119157A (ja) 2021-08-12
CN106456643A (zh) 2017-02-22
AU2020286314A1 (en) 2021-01-21
US10633385B2 (en) 2020-04-28
US11891392B2 (en) 2024-02-06
EP3662910B1 (en) 2024-09-18
KR20220163533A (ko) 2022-12-09
HRP20241680T1 (hr) 2025-02-28
PT3125898T (pt) 2020-04-01
EP3125898A1 (en) 2017-02-08
EP3662910A1 (en) 2020-06-10
HUE069651T2 (hu) 2025-03-28
SI3662910T1 (sl) 2025-05-30
WO2015153468A1 (en) 2015-10-08
JP2020002170A (ja) 2020-01-09
CN111499636B (zh) 2023-01-13
US10239877B2 (en) 2019-03-26
JP6756435B2 (ja) 2020-09-16
KR102611067B1 (ko) 2023-12-06
CA2944452A1 (en) 2015-10-08
RS66254B1 (sr) 2024-12-31
US20240190877A1 (en) 2024-06-13
EP4470617A3 (en) 2025-02-26
US20200283440A1 (en) 2020-09-10
RS60163B1 (sr) 2020-05-29
JP2023022184A (ja) 2023-02-14
AU2015241069A1 (en) 2016-10-20
AU2015241069B2 (en) 2020-10-15
CN111499636A (zh) 2020-08-07
PL3662910T3 (pl) 2025-08-11
KR20160138513A (ko) 2016-12-05
AU2022283729A1 (en) 2023-02-02
SMT202400497T1 (it) 2025-01-14
HRP20200478T1 (hr) 2020-07-24
US20220002300A1 (en) 2022-01-06
EP4470617A2 (en) 2024-12-04
KR102473930B1 (ko) 2022-12-05
JP7186256B2 (ja) 2022-12-08
US20170107221A1 (en) 2017-04-20
PT3662910T (pt) 2024-11-27
PL3125898T3 (pl) 2020-11-16
US20190284188A1 (en) 2019-09-19
SI3125898T1 (sl) 2020-07-31
JP7688245B2 (ja) 2025-06-04
CY1123093T1 (el) 2021-10-29
AU2024204977A1 (en) 2024-08-08
EP3125898A4 (en) 2017-08-16
CA3158795A1 (en) 2015-10-08
JP6873201B2 (ja) 2021-05-19
ES2999685T3 (en) 2025-02-26
CA2944452C (en) 2022-07-19
ES2779979T3 (es) 2020-08-21
DK3662910T3 (en) 2024-11-04
EP3125898B1 (en) 2019-12-25
SMT202000219T1 (it) 2020-05-08
LT3125898T (lt) 2020-04-10
FI3662910T3 (fi) 2024-10-31
CN106456643B (zh) 2020-04-17
DK3125898T3 (da) 2020-03-30
HUE049013T2 (hu) 2020-08-28
JP2017511321A (ja) 2017-04-20

Similar Documents

Publication Publication Date Title
LT3662910T (lt) Trail geno indukcijai skirtas farmakoforas
DK3102669T3 (da) Forbedret bacillevært
DK3233887T3 (da) Immunmodulatorer
PL3118311T3 (pl) Antysensowny kwas nukleinowy
HUE057846T2 (hu) Permanens epigenetikus géncsendesítés
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
MA39481A (fr) Thérapies ciblées
DK3188836T3 (da) Dna-syntese
HUE054784T2 (hu) 5-klór-2-difluor-metoxifenil-pirazolopirimidin vegyületek, amelyek JAK-gátlók
HUE054514T2 (hu) Kemence
HUE042087T2 (hu) Inhalátor
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
FR3025617B1 (fr) Architecture bi-voies
IL249254A0 (en) Gene expression system
EP3125821C0 (en) INSERT FOR AN INHALER
IL257500A (en) Altered cullin1 gene
LT3628731T (lt) Naujas antipresepsino antikūnas
IL252086A0 (en) Novel methods
SG11201609108TA (en) Antibody gene expression-secretion system
EP2993051A4 (en) PRINTER
BR112017008675A2 (pt) impressoras
ES1135593Y (es) Multibotella
UA28521S (uk) Наличка
ES1122680Y (es) Ladrillo caravista
UA31168S (uk) Інгалятор